Hoechst Marion Roussel to share P&G's Actonel development and marketing for osteoporosis.
Executive Summary
HOECHST MARION ROUSSEL TO PROMOTE P&G's ACTONEL (RISEDRONATE) under an agreement announced May 5. Hoechst will collaborate on final development of the osteoporosis and bone disorder agent and will help to market the drug in all countries except Japan. Procter & Gamble will receive milestone payments to offset development costs thus far for risedronate, the companies said. The two companies will share future expenses and revenues.